Statin-related muscle side effects are a constant healthcare problem since patient compliance is dependent on side effects. Statins reduce plasma cholesterol levels and can prevent secondary cardiovascular disease. Although statin-induced muscle damage has been studied, preventive or curative therapies are yet to be reported.
Introduction
Patient non-compliance to medication due to side effects is a major healthcare concern. Statin side effects on skeletal muscle causes about 70% of patients to discontinue treatment [1] [2] [3] [4] [5] [6] [7] . Millions of patients ingest statins to reduce blood cholesterol levels thereby preventing cardiovascular diseases.
Most statin-intolerant patients experience muscle cramps and myalgia, with occasional asymptomatic elevation of creatine kinase and weakness. Although skeletal muscle damage has been studied in mice 8 , it is unknown whether the same or different mechanisms underlie the various myopathic phenotypes and how we can circumvent or treat statin-induced changes in skeletal muscle. Also, the effect of lipophilic and/or hydrophilic statins on muscle is unclear. Removal of cholesterol might affect membrane structure and lipid rafts that are essential for signalling and cellular compartmentalization.
Given that, cholesterol-lowering agents including proprotein convertase subtilisin / kexin type 9inhibitors (PCSK9-inhibitors), would lead to the same spectrum of muscle complaints. Alternatively, statins might influence pathways downstream of the hydroxymethylglutaryl-coenzyme A (HMG-CoA) reduction into mevalonate by the reductase HMGCR that is inhibited by statins and causing a distinct myopathy 9, 10 .
Mevalonate can be metabolized into squalene for cholesterol biosynthesis 11 or into metabolites, i.e.
farnesyl-pyrophosphate and geranylgeranyl-pyrophosphate, involved in isoprenoid synthesis, protein prenylation, and ubiquinone synthesis. Consequently, hypotheses for statin-related side effects include a decrease in ubiquinone synthesis, cholesterol, and vitamin D levels, and a loss of isoprenoid metabolites. Altering vitamin D levels and protein ubiquination remain an intriguing yet controversial hypothesis for causing statin-induced side effects 10, [12] [13] [14] [15] . Interventions into isoprenoid synthesis have been associated with ATP depletion and DNA damage and therefore suggested for cancer therapy 16, 17 . Since ubiquinone is critical for the mitochondrial respiratory chain, mitochondrial impairment has been reported in vitro as well as in statin-treated patients 18 . Ubiquinone supplementation is argumentatively beneficial to patients 19 . However, most studies have been performed in non-human muscle or human non-muscle cell lines or animals and only focus on mevalonate depletion.
In this study, we asked whether there are key signalling pathways in muscle that are significantly interfered by statins and may have a statin myopathy management potential. We chose an integrated approach to study the effects of a lipophilic and a hydrophilic statin in many individual primary human myoblast cells at molecular, cellular, and functional levels 20 . We developed a new assay for mevalonate detection and showed that statins have a significant effect on gene and protein expression profiles. Our model for signal transduction pathway suggests statin-induced metabolic changes upstream of mevalonate, particularly in mitochondrial ß-oxidation and eicosanoid synthesis.
Eicosanoids have profound effects on inflammation, cell proliferation and differentiation, and acts as pain mediators. Primary human muscle cells secrete eicosanoids and prostaglandins in vitro.
Arachidonic acid derived eicosanoid levels changed time dependently. Furthermore, statins directly influence the proliferative and regenerative features of skeletal muscle cells. Eicosanoid-species substitution to statin-treated primary human muscle cells rescue these effects. Statin myopathy, therefore, appears as a distinct and potentially treatable myopathy driven by HMG-CoA accumulation rather than mevalonate depletion.
Results
In primary human muscle cell populations obtained from 25 patients we investigated key signalling pathways that are significantly interfered by statins in muscle cells and their impact on cellular and molecular levels.
Simvastatin more than rosuvastatin extensively alters myotube expressome
Transcriptome data obtained from statin-treated primary human myotubes group clearly separate from untreated and DMSO-treated samples on a PCA analysis plot ( Figure 1A) . A concern about studying primary human samples derived from individuals of different age and gender usually has been the potentially high variation between samples. Clinical patient information is provided in Supplementary   Table S1 . Here, however, we can show that primary human samples behave very similar among various conditions but different for both statins ( Figure 1A ). We found that simvastatin had a dramatic effect on primary human muscle cells, much more than rosuvastatin. 1807 genes (FDR<0.05) were differentially expressed after exposure to simvastatin ( Figure 1B , Supplementary Table S2 , Supplementary Data File 1). Simvastatin had a particularly strong impact on RNA metabolism (Table   1 ). The number of genes affected by rosuvastatin was only 68 (FDR<0.05) ( Supplementary Table S3 , Supplementary Data File 2) with a main impact on lipid and cholesterol metabolism. When transcriptome and proteome of identical samples are compared, there may or may not be a good overlap. We found that on proteome level 3255 skeletal muscle proteins were significantly identified after exposure to statins (Supplementary Figure S1 , Supplementary Data File 3; Supplementary Tables S5, S6 ). Proteins belonging to lipid metabolic, small molecule metabolic, and cellular, developmental as well as RNA metabolic processes were particularly affected (Supplementary Data File 4). A Venn diagram ( Figure 1C ) demonstrates that 19% of genes and proteins in simvastatin and 6% in rosuvastatin treated myotubes were significantly differentially expressed at proteome and transcriptome levels when compared to controls. Five gene products are differently regulated by both statins at mRNA as well as protein levels: Calsyntenin-2 (CLSTN2), lanosterol 14-alpha demethylase (CYP51A1), squalene synthase (FDFT1), isopentenyl-diphosphate delta-isomerase 1 (IDI1), and tubulin beta-2B chain (TUBB2B) ( Supplementary Table S7 ). All five are involved in cell adhesion and cholesterol biosynthesis. The degree of similarity between RNA-Seq and proteome-data is visualized in a circus plot (Supplementary Video) 21 .
The significant effect of statins on the transcriptome and proteome of primary human muscle cells was unexpected and widespread. Because both, simvastatin and rosuvastatin, induce "statin-myopathy"
we focussed our further analysis on pathways in muscle cells that were influenced by both statins.
These were fatty acid metabolism, fatty acid import, and lipid metabolic processes ( Table 1, Supplementary Data File 4). Supplementary Table S1 . See also Supplementary Figure S1 and Supplementary Data File 1 and 2.
Muscle cells possess a similar repertoire for cholesterol biosynthesis as liver
We next asked how the muscle was equipped to synthesize and metabolize cholesterol. We found key enzymes for cholesterol biosynthesis (HMGCS1, HMGCR, CYP51A1, DHCR7) as well as cholesterol transport (LDLR, ABCA1, ABCG1) expressed in human muscle cells and significantly altered by different exposure to statins. We further analysed the transcript variants of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) of human muscle cells and compared them to human liver (HepG2 cells) ( Figure 2A ). HMGCR transcript variants (ENST00000287936 and ENST00000343975 that excludes exon 13) have an impact on cholesterol metabolism regulation and statin efficacy 22 . The transcripts in primary human myotubes and HepG2 cells were identical (Figure 2A ). In our OMICs data set ( Supplementary Table S4 ) the ENST00000343975 was also detectable at low levels. We then tested to what extent statins added to primary human muscle cells would influence cholesterol and mevalonate levels, or expression of cholesterol dependent gene expression ( Figure 2B -D). To accomplish this, we redeveloped a simple assay for mevalonate determination in human muscle cells.
Cholesterol and mevalonate levels in primary human myotubes were significantly lowered by statins in a concentration dependent manner. ( Figure 2B and C). On mRNA level as assessed by qPCR, we found that statins increased HMGCS and HMGCR ( Figure 2D ), the same effects that have been described for liver including LDL receptor 23 . Eight protein coding transcript variants are known for LDLR. In our RNASeq data set, we found six of them differentially expressed (between statin and controls) with similar fold changes (see Supplementary Table S4) 
Statins interfere with fatty acid metabolism
To further analyze pathways significantly affected by both statins, we used Gene Ontology enRIchment anaLysis (GOrilla) and the Database for Annotation, Visualization and Integrated Discovery (DAVID) analysis (Supplementary Data File 4). Within the gene ontology terms fatty acid metabolism, fatty acid import, and lipid metabolic processes, we identified significant effects on genes involved in lipid, fatty acid, and arachidonic/ eicosanoid metabolism as well as on retinoic acid response of the retinoid X receptor's (RXR) pathway and carnitine shuttling ( Figure 3A ). Carnitine palmitoyltransferase I (CPT1) was up to 12-fold upregulated at protein level. Based on these findings, we qualitatively analysed gene and protein interactions known or predicted to HMGCR and included the quantitative abstraction level for pathway modelling. We modelled a regulatory network showing the statin-induced alterations on HMGCR-associated pathways in human muscle. (Figure 3B , Supplementary Table S8 ). Among the general impact of statins on acetyl-CoA dependent metabolic processes we found particularly interesting upregulation of fatty acid desaturases and elongases.
Both, fatty acid desaturases and elongases catalyse precursor molecules for prostaglandin and eicosanoid synthesis, molecules involved in inflammation, mitochondrial function, and mediating pain; a common finding in statin-induced myopathy. We propose that the statin effect in muscle may be driven by HMG-CoA and acetyl-CoA accumulation rather than a loss of mevalonate downstream metabolites.
Indeed, we found that a number of genes involved in eicosanoid synthesis, such as the ATP-binding cassette sub-family D member 1, the elongation of very long chain fatty acids 4 and 6 as well as the aldo-keto reductase family 1 member D1, fatty acid desaturase, phospholipase A2 group III, and prostaglandin-endoperoxide synthase 1 (PTGS1) were significantly different expressed ( Figure 3A,B ).
PTGS1 is constitutively expressed in a wide range of tissues and PTGS2 is the inducible isoform.
Significant reduction of PTGS1 ( Figure 3C ), but not PTGS2, the key enzyme in (error bar = mean with SD; n=11) See Supplementary Table S9 for PCR primer details. For cell populations used see Supplementary Table S1 . If an impairment in eicosanoid biosynthesis would be responsible for statin related side effects on muscle, reconstitution with eicosanoids might be beneficial. We first identified parameters on cellular level that would be possible to quantify and measured the effect of statins on proliferation and differentiation in primary human muscle cells. Myoblast proliferation decreased in response to both, simvastatin and rosuvastatin, in a concentration-dependent manner ( Figure 4A , Supplementary Figure   S2B ). We found no evidence for significant statin toxicity (Supplementary Figure S2A) or oxidative stress as measured by nitric oxide concentration ( Supplementary Figure S3A,B) . Rescue experiments with mevalonate and geranylgeranyl pyrophosphate demonstrate that the effect on proliferation was indeed statin specific (Supplementary Figure S2B ). In addition, both statins markedly delayed primary human myoblast differentiation as quantified by fusion index, and by myosin heavy chain expression on mRNA and protein level ( Figure 4B and C) . We then tested six different eicosanoid species at concentrations reported in the literature ( Supplementary Table S11 ) for their effect on proliferation and differentiation of primary human muscle cells during statin exposure. We identified AL-8810, an 11β-fluoro receptor analog of prostaglandin 2α, but not prostaglandin 2α, to significantly reverse the effect of simvastatin on proliferation and differentiation ( Figure 4D ). AL-8810 had no effect on rosuvastatin treated myotubes (Supplementary Supplementary Table S1 . [UT, untreated (black); Sim, simvastatin (red); Rosu, rosuvastatin (blue); MYHI, myosin heavy chain 1]
Discussion
In our comprehensive expressome analysis and molecular and cellular assessment of muscle related statin effects we discovered that statins have profound and unexpected effects on the transcriptome and proteome of primary human muscle cells. Some cellular functions such as RNA synthesis and turnover were much more influenced by the lipophilic simvastatin than by the hydrophilic rosuvastatin, but cholesterol and fatty acid metabolism, mitochondrial metabolism as well as eicosanoid synthesis pathways were severely affected irrespective of the class of statin that was delivered. The phenotype could be rescued by the addition of eicosanoids.
We were surprised to find a dramatic effect of statins on cholesterol and eicosanoid synthesis in primary human muscle cells. We investigated the cellular gene set to synthesise cholesterol and found that muscle and liver cells (HepG2) share the same repertoire for cholesterol biosynthesis (i.e. HMGCS1, HMGCR, CYP51A1, DHCR7) and transport (i.e. ABCA1, ABCG1, LDLR). Besides SCARB1, cholesterol biosynthesis proteins have been positively detected in human skeletal muscle (https://www.proteinatalas.org) [53] . It possibly points towards a so far underestimated role of skeletal muscle for their own cholesterol homeostasis 24 . It might be possible that muscle synthesizes cholesterol to the same or a larger degree as liver. The human body consists of more than 25% muscle mass, whereas the liver only makes up 2-3%. If cholesterol synthesis is an integral part of muscle function, it would be interesting to speculate whether muscular cholesterol is also secreted into the blood circulation or whether skeletal muscle only produces cholesterol for its own needs. It will be the role of future experiments employing in vivo microdialysis 25 together with metabolomic plus lipidomic analysis that will provide the necessary answers.
Genes involved in cholesterol metabolism like HMGCR, HMGCS1, LDLR, and PCSK9 are increased under statin treatment in primary human muscle cells 26 . If HMG-CoA synthesis is increased but its reduction inhibited by statins, HMG-CoA levels increase and accumulate 27 . Therefore, HMG-CoA might reconvert into ketone metabolites, namely acetoacetyl-CoA and Ac-CoA. Acetoacetyl-CoA synthetase and Ac-CoA acetyltransferase expression are increased suggesting ketolysis or Ac-CoA formation. Muscle is not known to be able to produce ketone bodies whereas liver would be. In rat hepatocytes, high Ac-CoA concentrations trigger insulin resistance in vivo 28 . Excess Ac-CoA has been also observed in diabetes patients as insulin negatively regulates gluconeogenese by suppressing Ac-CoA [34] . Indeed, clinical observations associate statins with an increased risk for diabetes mellitus type-2 [29] [30] [31] . Ac-CoA is a central metabolite. Multiple metabolic effects are possible and are intermingled between each other. Increased Ac-CoA would shuttle into the tricarboxylic acid cycle, carnitinepalmitoyl-transferases (CPT1) as well as fatty acid and triglyceride biosynthesis ( Figure 5 ). All pathways appear affected by statins in muscle as we find increased protein levels of Ac-CoA carboxylase alpha, a very prominent upregulation of CPT1, and an influence on key enzymes for fatty acid synthesis and mitochondrial ß-oxidation ( Supplementary Table S8 , Figure 5 ). On the one hand, Ac-CoA carboxylase alpha, an ACC family member, converts Ac-CoA into malonyl-CoA (Mal-CoA), the primary substrate for fatty acid biosynthesis. Mal-CoA inhibits CPT1 for ß-oxidations. On the other hand, Ac-CoA can be metabolised by ACC and fatty acid synthase via transformation of palmitic acid and various fatty acids into acyl-CoA for ß-oxidation. Active CPT1 shuttles acyl-CoA into the inner mitochondrial vortex for ß-oxidation 31 . In rodents, high CPT1 levels have been shown to induce mitochondrial overload by acyl-carnitine accumulation with excess ß-oxidation leading to insulin resistance 32 and mitochondrial stress 33 . High CPT1 values in statin-treated primary human myotubes may hint towards altered ß-oxidation and mitochondrial impairment. Insulin resistance under statin treatment would be interesting for further studies.
In the cytosol, fatty acid synthases, desaturases, and elongases synthesize long-chain fatty acids by using Mal-CoA and Ac-CoA. Fatty acid desaturases catalyse the formation of arachidonic acid and eicosapentanoic acid, the precursor of prostaglandins (PG) and eicosanoids. These molecules have multiple effects including influences on cell proliferation and differentiation 34 , inflammation, mitochondrial function, and being pain mediators, a very frequent complaint of statinusers. The degree of statin influence on prostaglandin and eicosanoid synthesis was striking at molecular level, i.e. on fatty acid desaturases, elongases, de-/carboxylases (see Supplementary Table   S8 , Figure 5 ). We concentrated our further investigation on the formation of prostaglandins (PG) and eicosanoids. As the next important enzyme being significantly downregulated, PTGS1 (COX1)
converts ω -6 derived arachidonic acid into biological active eicosanoids and PGs, i.e. PGE2, PGD2, and PGF2a. PTGS is interesting because nonsteroidal anti-inflammatory drugs such as ibuprofen inhibit PTGS and are relevant for pain management 35 . PTGS-inhibitors influence on human skeletal muscle is controversially reported 34, [36] [37] [38] . In older patients performing resistance exercise under PTGSinhibition treatment, Type I fiber size increased up to 28% compared to control group 38 . Beneficial effects on skeletal muscle performance have been reported for PTGS up-regulation at mRNA level 39 .
Decreased satellite cell fusion after PTGS1 inhibition has been observed in rats 40 . We found that PTGS1 expression is associated with reduced differentiation of simvastatin-treated primary human myotubes. PTGS1 is suggested as the only source for PGF2a 41 derived from arachidonic acid. PGF2a acts pro-inflammatory but at the same time suggested to promote murine myoblasts fusion and proliferation 42, 43 . Its inhibition is proposed to significantly diminish murine myoblast fusion as suggested by Horsely et al 42 . Contrary to the data in animals, Brewer et al. found no significant effect in human skeletal muscle with PGF2a metabolite inhibition and any negative effect diminished over time 34 . In our study, treatment with PGF2a did not significantly change myoblast proliferation and differentiation under statin treatment but PGF2a secretion initially increased under simvastatin treatment together with PGD2, another proinflammatory PG. In a clinical study, eccentric resistance exercise initially revealed high PGF2a levels in human skeletal muscle biopsy specimens 44 . PGD2 metabolites are also linked to DMD suggesting a role in muscle cell pathology 45 . Our findings support data obtained from human skeletal muscle 36 rather than from mice and rats 40, 42 . Inflammation surprising. Beside its activating capability for peroxisome proliferator-activated receptors and G protein coupled receptor, 13-HODE is speculated for mitochondria dysfunction and altered calcium homeostasis in epithelia cells 47 . There is currently no information for 13-HODE in skeletal muscle cells but may be another intriguing candidate to be studied in myoblast fusion. Taken together, lipid profiles from supernatant of statin-treated primary human muscle cells under fusion condition show increase in ω -6 arachidonic acid metabolites. However, supplements with ω -3 eicosapentanoic acid and docosahexaenoic acid, but not ω -6, are reported to improve skeletal muscle damage, stiffness and regeneration [48] [49] [50] . In vivo studies in elderly human probands and insulin-resistant non-diabetic patients, ω -3 PUFA supplementation had no effect on mitochondrial function 48, 51 but improved mitochondrial ADP kinetics and insulin sensitivity in young, healthy adults 52 . Pre-treatment with ω -3 fatty acid eicosapentanoic acid but not docosahexaenoic acid stimulates fatty acid ß-oxidation and glucose transport in human myotubes 53 .
Here, we showed that AL-8810, a PGF2a-receptor agonist 34 , positively influences statin-induced effects on muscle cell proliferation and differentiation. We speculate that AL-8810 quenches excess levels of PGF2a, initially secreted by simvastatin treated primary human myoblasts at a critical time point for fusion. We believe that our bench side findings could be translated into the clinic. Very recently, a clinical study showed that eicosapentanoic acid and docosahexaenoic acid added to statin therapy to prevent enlargement of carotid plaques, also significantly reduced severe and less severe musculoskeletal side effects, in particular myalgia 54 . Our study provides an explanation and supports the notion that ω -3 fatty acids should be added to statin therapy either as a prevention or as a treatment of statin myopathy. Patients may be less inclined to discontinue treatment when statin muscular side effects including pain are reduced.
Materials and Methods

Primary human myoblasts and cell populations
Muscle biopsy specimens for myoblast isolation were obtained from M. vast. lat. after IRB approval by the regulatory agencies (EA1/203/08 and EA2/051/10, Charité Universitätsmedizin Berlin, in compliance with the Declaration of Helsiniki) at the Helios Hospital Berlin Buch, Berlin, Germany, for diagnostic or orthopedic reasons. All study participants provided informed consent. Human muscle biopsy material is restricted regarding availability and quantity, also for ethical reasons. Experiments were conducted from a total of 25 different primary human myoblast cultures ( Supplementary Table   S1 ). All cells used in this study were maintained at 37 °C in 5% CO2. For all experiments, except for eicosanoid substitutions, we only used primary muscle cells obtained from statin naïve individuals.
Statin-myopathy patients had myalgias (>3 of 10 on a visual analogue scale) and/ or creatine kinase levels elevated to > 250 IU/l under therapy. Isolation was performed as described 55 . The percentage of fibroblasts in myoblast cultures was always below 5% as assessed by anti-desmin staining.
Differentiation into myotubes was induced using Opti-MEM (Invitrogen, Germany).
We controlled for confounding factors including cell culture, sample handling, and biopsy-stress variations. At least two to a maximum of four cell populations were used simultaneously in an experimental setup by the same experimenter. In an experimental setup, controls and both statins were completed simultaneously.
Pharmacological reagents
The active form of simvastatin was purchased from ARC (Missouri, USA), rosuvastatin from LKT Laboratories (Minnesota, USA), fatty acid species from Cayman Chemical (Michigan, USA).
Geranylgeranyl-pyrophosphate, mevalonolactone, and mevalonic acid were from Sigma Aldrich (Germany). Both statins were dissolved in DMSO and tested for their functionality at different concentrations (1-50µM). ( Supplementary Table S11 )
Treatment of myoblast and myotubes
Primary human myoblasts were cultured in skeletal muscle growth medium (ProVitro, Berlin, Germany) in 96 well plates (3 x 10^3 cells/ well). Test substances were applied 24 h after plating ( Supplementary Table S11 ). Every 24 h, the cells were refed with fresh medium in the presence or absence of test compounds. All treatments were performed in parallel for each cell population at the same time of the day to exclude circadian rhythm effects. Proliferation was quantified by the colorimetric BrdU assay (Roche, Germany). Toxicity was assessed using the ToxiLight™ Non- Table S12 , Supplementary Figure S6) 
RNA analyses
RNA was isolated using the NucleoSpin® RNA/Protein Kit (Marcherey-Nagel, Germany). RNA quantity and purity were determined using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, USA). For qPCR, the mRNA was reverse transcribed using the QuantiTect reverse transcription kit (Qiagen, Germany). qPCR was performed according to MIQE guidelines 56 Figure S1 ). Trimmed reads were aligned to human reference genome (GRCh37) and mapped back to the human transcriptome (v. 19 ).
Mapped read counts were statistically analyzed using the R packages EdgeR and DESeq for matched sample data 57 . Samples without any and with DMSO treatment were considered as reference group.
Gene expression data from simvastatin and rosuvastatin treated samples with FDR<0.05 (Bonferroni) were considered as statistically significantly different from control groups. Data are stored at Gene Expression Omnibus -GSE107998.
Transcriptional profiling can be influenced by unintentional factors. We controlled for confounding factors including individual differences, muscle biopsy variations, and sample composition. The muscle cell population were obtained from age-matched donors from the same ethnic group during an orthopaedic surgery. Gender specific genes were removed for RNAseq statistic. qPCR analyses verified RNAseq expression results of selected candidate genes.
Deep proteome analysis
Proteins were prepared according to Sapcariu et al 58 . Samples were measured by LC-MS/MS on a Q-Exactive orbitrap mass spectrometer (Thermo Scientific, Germany). For the data analysis, the MaxQuant software package version 1.4.1.2 was used, with a multiplicity of 3 for dimethylation analysis (modified epsilon amino groups of lysine plus modified N-terminal amino groups) 59 .
Carbamidomethylation was set as a fixed modification while oxidized methionine and acetylated Ntermini were set as variable modifications. An FDR of 0.01 was applied for peptides and proteins search was performed using a human Uniprot database (August 2013). Normalized ratios of the protein groups output were used to determine proteins which are obviously regulated. (Supplementary Figure S1) 
Cell quantification
Myotube fusion and maturation were quantified using an LSM 700 AxioObserver Z1 (Zeiss, Germany) and an N-Achroplan 10x/0.25 M27 objective. Image files were exported and converted in batch into black-white images with adjusted gray-scale using IrfanView (v. 4.38) . Separate image files for MYHCf and HOECHST 33258 were loaded into the CellProfiler software (v 2.1.1) 60, 61 . A pipeline for calculating multinucleated cells was used and slightly modified 62 . A myotube was defined having more than three nuclei. The fusion index was calculated by the number of nuclei in myotubes divided by the total number of nuclei counted in each image. The maturation index is described by the average number of nuclei per myotube.
Data visualization for RNA-Seq and deep proteome
For analyses with mapped count data apart from the EdgeR or DESeq package, mapped read counts were exported from CLC Genomics Workbench (v 7.5.1) and normalized for their library size using the trimmed mean of M-values normalization approach (TMM) 63 . Differential gene expression data were plotted as dendogram clustered heatmaps using GENE-E (v 3.0.206) 64 . Plot.ly was used to visualize quality check data. Principal component analysis was performed in discriminate gene expression data for each treatment group with ClustVis (release June 2016) 65 . Venny 2.0 was used to generate the Venn diagram 66 . The Circos-Plot for omics data was generated using the Bioconductor package OmicCircos 67 .
Pathway analyses
Statistically significant, differential gene expression data from simvastatin and rosuvastatin treated myotubes and controls were further analysed with GOrilla (release March 2013), Reactome (v 53), and DAVID (v 6.7) to identify enriched GO terms and pathway clustering [68] [69] [70] . Gene lists were ranked regarding their expression value. In addition, the web-based Ingenuity pathway analysis application (IPA; Ingenuity Systems, Redwood City, CA) was used.
Statistics
All statistics for RNA-Seq and proteome data analyses were performed using RStudio (v 0.98.1006)
for executing R packages (v 3.1.1). Statistical analyses for proliferation, toxicity, and qPCR data were 
